With new PhIII data in hand, Dermavant lines up topical psoriasis contender for a sprint to the finish line

Nicole DeFeudis

Editor

In the next couple months, Dermavant CEO Todd Zavodnick says he’ll sprint to the FDA with tapinarof, the company’s “cosmetically elegant” vanishing cream to treat …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With new PhIII data in hand, Dermavant lines up topical psoriasis contender for a sprint to the finish line

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

With new PhI­II da­ta in hand, Der­ma­vant lines up top­i­cal pso­ri­a­sis con­tender for a sprint to the fin­ish line

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

With new PhIII data in hand, Dermavant lines up topical psoriasis contender for a sprint to the finish line